Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $32 to $34.
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $32 to $34.